Company intelligence / Profile preview

BioVersys AG

Basel, Basel-Stadt, Switzerlandbioversys.com ↗

Ownership: Public · BIOV
Development stage: Phase 2

Overview

BioVersys has advanced its lead asset BV100 into Phase 2 clinical trials targeting carbapenem-resistant Acinetobacter baumannii. Alpibectir for tuberculosis is in Phase 2a trials through a partnership with GSK and the University of Lille. The company’s pipeline includes additional preclinical assets targeting S. aureus and NTM infections. Its platforms focus on overcoming antimicrobial resistance via novel mechanisms of action.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

BV100

2 more assets in the full pipeline.

Request access →

Partnerships

GlaxoSmithKline (GSK) – co-development of alpibectir for tuberculosis with University of Lille consortiumGIBF – strategic investment and support for China clinical expansion of BV100

Beyond the preview

Go deeper on BioVersys AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioVersys AG.

Explore the full profile